John Gubatan1, Kyle Staller2,3, Kenneth Barshop4, Braden Kuo2,3. 1. Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA, 02215, USA. jgubatan@bidmc.harvard.edu. 2. Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 3. Center for Neurointestinal Health, Massachusetts General Hospital, Boston, MA, USA. 4. Pritzker School of Medicine, University of Chicago, Chicago, IL, USA.
Abstract
BACKGROUND: The role of cannabinoids in gastrointestinal diseases is controversial and of great interest, yet their use in patients has not been critically examined. AIM: To determine the prevalence and effects of cannabis abuse on healthcare utilization, as measured by emergency department (ED) visits, in a large, tertiary gastroenterology practice. METHODS: All patients seen in the gastroenterology clinic at a tertiary care center during a 27-year period (1986-2013) were included in our study to determine the overall prevalence of cannabis abuse. We matched cannabis abusers 1:2 with non-abusing controls to determine the effect of cannabis on ED utilization, our primary outcome. We used multivariate linear regression to adjust for confounders and define the independent effect of cannabis abuse on ED utilization. RESULTS: Our prevalence study cohort included 190,303 GI clinic patients with an overall cannabis abuse prevalence of 0.80 % (1520 patients). From 1986 to 2012, the prevalence of cannabis abuse in this clinic increased by 0.73 % (0.03 %/year) (p < 0.0001). From the 1520 cannabis abusers identified, 467 patients were randomly selected as cases and were matched to 934 controls. From this retrospective cohort, the median ED visits/year for cannabis abusers was 1.88 versus 0.89 for non-abusers (p < 0.0001). After multivariate adjustment, cannabis abuse was associated with a 1.47-fold increase (95 % CI 1.23-1.76, p < 0.0001) in median ED visits/year. CONCLUSIONS: Reported cannabis abuse in GI clinic patients is less prevalent than in the adult US population, but is increasing. Cannabis abuse among gastroenterology patients is associated with increased ED visits.
BACKGROUND: The role of cannabinoids in gastrointestinal diseases is controversial and of great interest, yet their use in patients has not been critically examined. AIM: To determine the prevalence and effects of cannabis abuse on healthcare utilization, as measured by emergency department (ED) visits, in a large, tertiary gastroenterology practice. METHODS: All patients seen in the gastroenterology clinic at a tertiary care center during a 27-year period (1986-2013) were included in our study to determine the overall prevalence of cannabis abuse. We matched cannabis abusers 1:2 with non-abusing controls to determine the effect of cannabis on ED utilization, our primary outcome. We used multivariate linear regression to adjust for confounders and define the independent effect of cannabis abuse on ED utilization. RESULTS: Our prevalence study cohort included 190,303 GI clinic patients with an overall cannabis abuse prevalence of 0.80 % (1520 patients). From 1986 to 2012, the prevalence of cannabis abuse in this clinic increased by 0.73 % (0.03 %/year) (p < 0.0001). From the 1520 cannabis abusers identified, 467 patients were randomly selected as cases and were matched to 934 controls. From this retrospective cohort, the median ED visits/year for cannabis abusers was 1.88 versus 0.89 for non-abusers (p < 0.0001). After multivariate adjustment, cannabis abuse was associated with a 1.47-fold increase (95 % CI 1.23-1.76, p < 0.0001) in median ED visits/year. CONCLUSIONS: Reported cannabis abuse in GI clinic patients is less prevalent than in the adult US population, but is increasing. Cannabis abuse among gastroenterology patients is associated with increased ED visits.
Entities:
Keywords:
Cannabinoids; Cannabis; Epidemiology; Functional GI disorders; Healthcare utilization; Medical marijuana
Authors: Mark Lemstra; Norman R Bennett; Cory Neudorf; Anton Kunst; Ushasri Nannapaneni; Lynne M Warren; Tanis Kershaw; Christina R Scott Journal: Can J Public Health Date: 2008 May-Jun
Authors: D A Revicki; A M Rentz; D Dubois; P Kahrilas; V Stanghellini; N J Talley; J Tack Journal: Aliment Pharmacol Ther Date: 2003-07-01 Impact factor: 8.171
Authors: J E Beal; R Olson; L Laubenstein; J O Morales; P Bellman; B Yangco; L Lefkowitz; T F Plasse; K V Shepard Journal: J Pain Symptom Manage Date: 1995-02 Impact factor: 3.612
Authors: Andrea Bollom; Jasmine Austrie; William Hirsch; Judy Nee; Daniel Friedlander; Johanna Iturrino; Sarah Ballou; Anthony Lembo Journal: J Clin Gastroenterol Date: 2018-10 Impact factor: 3.062
Authors: Theresa E Matson; Gwen T Lapham; Jennifer F Bobb; Eric Johnson; Julie E Richards; Amy K Lee; Katharine A Bradley; Joseph E Glass Journal: Drug Alcohol Depend Date: 2020-08-08 Impact factor: 4.492